Collegium Pharm Inc Company Profile
✉ Email this page to a colleague
What is the competitive landscape for COLLEGIUM PHARM INC, and what generic alternatives to COLLEGIUM PHARM INC drugs are available?
COLLEGIUM PHARM INC has four approved drugs.
There are twenty-seven US patents protecting COLLEGIUM PHARM INC drugs.
There are two hundred and eighty-eight patent family members on COLLEGIUM PHARM INC drugs in thirty-seven countries and fifteen supplementary protection certificates in twelve countries.
Summary for Collegium Pharm Inc
| International Patents: | 288 |
| US Patents: | 27 |
| Tradenames: | 3 |
| Ingredients: | 2 |
| NDAs: | 4 |
Drugs and US Patents for Collegium Pharm Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Collegium Pharm Inc | XTAMPZA ER | oxycodone | CAPSULE, EXTENDED RELEASE;ORAL | 208090-002 | Apr 26, 2016 | RX | Yes | No | 10,525,052 | See Plans and Pricing | Y | See Plans and Pricing | |||
| Collegium Pharm Inc | XTAMPZA ER | oxycodone | CAPSULE, EXTENDED RELEASE;ORAL | 208090-001 | Apr 26, 2016 | RX | Yes | No | 7,771,707 | See Plans and Pricing | Y | See Plans and Pricing | |||
| Collegium Pharm Inc | XTAMPZA ER | oxycodone | CAPSULE, EXTENDED RELEASE;ORAL | 208090-002 | Apr 26, 2016 | RX | Yes | No | 8,758,813 | See Plans and Pricing | See Plans and Pricing | ||||
| Collegium Pharm Inc | XTAMPZA ER | oxycodone | CAPSULE, EXTENDED RELEASE;ORAL | 208090-001 | Apr 26, 2016 | RX | Yes | No | 10,525,052 | See Plans and Pricing | Y | See Plans and Pricing | |||
| Collegium Pharm Inc | XTAMPZA ER | oxycodone | CAPSULE, EXTENDED RELEASE;ORAL | 208090-002 | Apr 26, 2016 | RX | Yes | No | 8,840,928 | See Plans and Pricing | Y | See Plans and Pricing | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Collegium Pharm Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Collegium Pharm Inc | NUCYNTA ER | tapentadol hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 200533-005 | Aug 25, 2011 | 6,071,970 | See Plans and Pricing |
| Collegium Pharm Inc | NUCYNTA ER | tapentadol hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 200533-001 | Aug 25, 2011 | 6,071,970 | See Plans and Pricing |
| Collegium Pharm Inc | NUCYNTA ER | tapentadol hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 200533-004 | Aug 25, 2011 | 6,071,970 | See Plans and Pricing |
| Collegium Pharm Inc | NUCYNTA | tapentadol hydrochloride | SOLUTION;ORAL | 203794-001 | Oct 15, 2012 | 6,071,970 | See Plans and Pricing |
| Collegium Pharm Inc | NUCYNTA | tapentadol hydrochloride | TABLET;ORAL | 022304-002 | Nov 20, 2008 | 6,071,970 | See Plans and Pricing |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for COLLEGIUM PHARM INC drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Tablets | x50 mg, 75 mg, and 100 mg | ➤ Subscribe | 2012-11-20 |
| ➤ Subscribe | Oral Solution | 20 mg/mL | ➤ Subscribe | 2013-12-20 |
| ➤ Subscribe | Oral Solution | 20 mg/mL | ➤ Subscribe | 2013-12-30 |
| ➤ Subscribe | Extended-release Tablets | 50 mg, 100 mg, 150 mg, 200 mg, and 250 mg | ➤ Subscribe | 2012-11-20 |
International Patents for Collegium Pharm Inc Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Slovenia | 1612203 | See Plans and Pricing |
| Croatia | P20170746 | See Plans and Pricing |
| Hungary | T74100 | See Plans and Pricing |
| Cyprus | 1106929 | See Plans and Pricing |
| World Intellectual Property Organization (WIPO) | 2004004693 | See Plans and Pricing |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Collegium Pharm Inc Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0693475 | 1190004-0.L | Sweden | See Plans and Pricing | PRODUCT NAME: TAPENTADOL; NAT. REG. NO/DATE: 42622-42628 20100910; FIRST REG.: DE 7543-7548,7661-76270" EESGODKLANDKOD="DE" EESGODKDATUM="2010-08-19" SEGODKNR="42622-42628 20100819 |
| 0693475 | CR 2010 00036 | Denmark | See Plans and Pricing | PRODUCT NAME: TAPENTADOL ((1R-2R)-3-(3-DIMETHYLAMINO-1-ETHYL-2-METHYL-PROPYL)-PHENOL), HERUNDER HYDROCHLORIDET; NAT. REG. NO/DATE: 45151-45158, 45162-45169 20100830; FIRST REG. NO/DATE: EU 75043.00.00-75048.00.00, 75261.00.00-75270.00.00 20100819 |
| 0693475 | PA2011007 | Lithuania | See Plans and Pricing | PRODUCT NAME: TAPENTADOLUM; NAT. REGISTRATION NO/DATE: LT/1/10/2341/001 - LT/1/10/2341/66, 2011 02 19; LT/1/10/2342/001 - LT/1/10/2342/110 20110219; FIRST REGISTRATION: 75043.00.00 - 75048.00.00, 2010 08 19; 76261.00.00 - 76270.00.00 20100819 |
| 0693475 | 2011/010 | Ireland | See Plans and Pricing | PRODUCT NAME: TAPENTADOL IN BASIC FORM OR IN THE FORM OF A SALT OF A PHYSIOLOGICALLY COMPATIBLE ACID, ESPECIALLY TAPENTADOL HYDROCHLORIDE; NAT REGISTRATION NO/DATE: PA1189/007/001-008 20101221; FIRST REGISTRATION NO/DATE: PA1189/008/001-008 21/12/2010 GERMANY 75043.00.00 75044.00.00 75045.00.00 19/08/2010 GERMANY 76261.00.00 76262.00.00 76263.00.00 76264.00.00 76265.00.00 19/08/2010 GERMANY 75046.00.00 75047.00.00 75048.00.00 19/08/2010 GERMANY 76266.00.00 76267.00.00 76268.00.0076269.00.00 76270.00.00 20100819 |
| 0693475 | SPC/GB11/031 | United Kingdom | See Plans and Pricing | PRODUCT NAME: TAPENTADOL IN THE FORM OF ITS BASE OR A SALT OF A PHYSIOLOGICALLY COMPATIBLE ACID, ESPECIALLY THE HYDROCHLORIDE SALT.; REGISTERED: DE 75043 20100819; UK PL 21727/0032 - 0050 20110204 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
